The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

Oncotarget
Min HeGen-Hong Di

Abstract

We aimed to evaluate the prognostic value of the lymph node ratio (LNR) in patients with axillary lymph node-positive triple-negative breast cancer (TNBC). The prognostic efficacy was investigated in the first cohort from the Surveillance, Epidemiology, and End Results (SEER) dataset (n=4114) and was further validated in an independent cohort from Fudan University Shanghai Cancer Center (n=417). Patients were classified into low-, medium- and high-risk LNR groups. Multivariate analysis revealed that the LNR was an independent predictor of overall survival (hazard ratio (HR) for high-risk LNR: 3.24; 95% confidence interval (CI): 2.56 to 4.09) and breast cancer-specific survival (HR for high-risk LNR: 3.57; 95% CI: 2.76 to 4.62) in the SEER population and also for disease-free survival (HR for high-risk LNR: 4.29; 95% CI: 2.24-8.21) in the validation population. Subgroup analysis revealed that patient classification according to the LNR could discriminate among groups of patients with different survival rates based on pathological nodal (pN) staging. The LNR shows potential for use as an additional prognostic factor for TNBC patients with positive lymph node involvement. Considering the heterogeneity of TNBC, use of the LNR might...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Eva SingletaryFrederick L Greene
Sep 10, 2002·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·B C H van der WalM A Boermeester
Apr 6, 2004·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Mia VoordeckersGuy Storme
May 11, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Eva GrunfeldUNKNOWN Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wendy A WoodwardYago Nieto
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce G HafftyDeborah Toppmeyer
Dec 6, 2006·Cancer·Emad A RakhaIan O Ellis
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul L NguyenJay R Harris
Jan 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vincent Vinh-HungChristine Bouchardy
Dec 17, 2009·Future Oncology·Vincent Vinh-HungGabriel N Hortobagyi
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Jun 25, 2010·Breast Cancer Research and Treatment·Jung Ah LeeUNKNOWN Korean Breast Cancer Society
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonel F Hernandez-AyaAna Maria Gonzalez-Angulo
Aug 19, 2011·Annals of Surgical Oncology·Anees B ChagparDavid L Rimm
Mar 1, 2011·Radiology and Oncology·Tanja OvcaricekSimona Borstnar
Oct 18, 2013·Annals of Surgical Oncology·Lauren E WizniaAnees B Chagpar
Feb 22, 2014·Annals of Surgical Oncology·Lauren StewardJulie A Margenthaler
Sep 7, 2014·American Journal of Surgery·Guo-Shiou LiaoJyh-Cherng Yu

❮ Previous
Next ❯

Citations

Oct 27, 2020·Frontiers in Oncology·Wen-Fen FuChuan-Gui Song
Aug 10, 2021·Current Cancer Drug Targets·Ajaz Ahmad WazaNaseer Ue Din Shah

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection

Software Mentioned

tile
SPSS

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.